| AAPBA | 3-acrylamidophenylboronic acid |
| AD | Alzheimer’s disease |
| AI | artificial intelligence |
| BACE1 | beta-site amyloid precursor protein cleaving enzyme 1 |
| BCS | Bio-pharmaceutics Classification System |
| CPL | Carboxymethyl agarose modified with 3-amino-Phenylboronic acid and L-valine |
| CSF | cerebrospinal fluid |
| ELISA | enzyme-linked immunosorbent assays |
| EMA | European Medicines Agency |
| EVs | extracellular vesicles |
| FCS | fluorocarbon-modified chitosan |
| GI | gastrointestinal |
| GMP | Good Manufacturing Practices |
| HA | hyaluronic acid |
| HCQ | hydroxychloroquine |
| HME | hot melt extrusion |
| Ins-CPL | Insulin-loaded hydrogel |
| LC-MS/MS | liquid chromatography–tandem mass spectrometry |
| LDH | lactate dehydrogenase |
| MRI | magnetic resonance imaging |
| NGS | next-generation sequencing |
| NIPAM | N-isopropylacrylamide |
| OATP | organic anion transporting polypeptides |
| PCQ | polymeric chloroquine |
| PCR | polymerase chain reaction |
| PDX | patient-derived xenograft |
| PET | positron emission tomography |
| ROS | reactive oxygen species |
| TCGA | The Cancer Genome Atlas |
| UGTs | UDP-glucuronosyltransferases |
| US FDA | U.S. Food and Drug Administration |